Back

Evaluating the efficacy and safety of beta-3 adrenergic receptor agonists in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials

12 May 2024 (09:00 - 10:08)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - treatment 2 Treatment HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Mr Lucas Rezende De Freitas

(Brazil)

6 More presentations in this session

Presentation thumbnail
Assessment of remote patient monitoring in patients with chronic heart failure across four European sites
Ms M. Verket (Aachen, DE)
Abstract Slides Video
Presentation thumbnail
Exploring the relationship between EuroSCORE II and aortic calcification in predicting clinical outcomes following cardiac surgery
Ms A. Pacheco (Aveiro, PT)
Abstract Slides Video
Presentation thumbnail
A real-world population with HFrEF treated with dapagliflozin or empagliflozin: a comparative analysis with DAPA-HF and EMPEROR REDUCED studies
Doctor E. Salvioni (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Assessment of treatment adherence in patients with chronic heart failure using the 8-item Morisky Medication Adherence Scale (MMAS-8)
Doctor A. Baigozhina (Astana, KZ)
Abstract Slides Video
Presentation thumbnail
Sodium reduction with low-sodium umami-flavoured bread in chronic heart failure: a randomized clinical pilot study.
Doctor F. Gommans (Veldhoven, NL)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - treatment 2

The Event

Event poster

Heart Failure 2024

12 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Selective beta-3 stimulation with mirabegron improves myocardial function and perfusion in a swine model of hibernated myocardium
thumbnail
Congress Presentation
MRAs in heart failure - An individual patient data meta-analysis of randomised trials
thumbnail
Congress Presentation
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources